MedTrace Logo

Micro Glucagon During Exercise in Type 1 Diabetes

NCT04192019 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2023-09-01

No results posted yet for this study

Summary

This proof-of-principle study to assess effects of different doses (mini and micro) of subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change in blood glucose concentration during moderate-intensity exercise in people with T1D.

Conditions

Interventions

DRUG

Micro-glucagon

Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise

DRUG

Mini-glucagon

Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Christoph Stettler, MD · Clinic Director

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2024-04-30
Completion
2024-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04192019 on ClinicalTrials.gov